References
- Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5. https://doi.org/10.1126/science.1100369
- Chen W, Zhang R, Zhang S, et al (2013). The incidences and mortalities of major cancers in China, 2009. Chin J Cancer, 32, 106-12. https://doi.org/10.5732/cjc.013.10018
- Dougan M, Dranoff G (2009). Immune therapy for cancer. Annu Rev Immunol, 27, 83-117. https://doi.org/10.1146/annurev.immunol.021908.132544
- Hontscha C, Borck Y, Zhou H, et al (2011). Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 137, 305-10. https://doi.org/10.1007/s00432-010-0887-7
- Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. A Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jiang J, Xu N, Wu C, et al (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res, 11, 2237-42.
- Jiang JT, Shen YP, Wu CP, et al (2010). Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol, 11, 6155-62.
- Jin CG, Chen XQ, Li J, et al (2013). Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. Asian Pac J Cancer Prev, 14, 6229-34.
- Kim HM, Lim J, Park SK, et al (2007). Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol, 7, 1802-7. https://doi.org/10.1016/j.intimp.2007.08.016
- Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33. https://doi.org/10.1007/s00262-012-1260-2
- Lin J, Zhu H, Lu X, et al (2010). Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med, 49, 2341-6. https://doi.org/10.2169/internalmedicine.49.3996
- Olioso P, Giancola R, Di Riti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 11, 130-9.
- Schmidt-Wolf IG, Finke S, Trojaneck B, et al (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer, 11, 1009-16.
- Schmidt-Wolf IG, Lefterova P, Mehta BA, et al (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 21, 1673-9.
- Schmidt-Wolf IG, NR, Kiem HP, et al (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity. J Exp Med, 174, 139-49. https://doi.org/10.1084/jem.174.1.139
- Stroncek D, Berlyne D, Fox B, et al (2010). Developments in clinical cell therapy. Cytotherapy, 12, 425-8. https://doi.org/10.3109/14653240903511952
- Sun Y, Liao M, Cheng G (2011). NCCN nonsmall-cell lung cancer clinical practice guidline:Chinese edition vesion. Beijing.
- Wu C, Jiang J, Shi L, et al (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 11, 3997-4002.
- Zheng YW, Li RM, Zhang XW, et al (2013). Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest, 31, 197-205. https://doi.org/10.3109/07357907.2013.775294
- Zhong R, Han B, Zhong H (2013). A prospective study of the efficacy of a combination of autologous endritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol, [Epub ahead of print].
Cited by
- Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2419
- Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis vol.34, pp.26, 2016, https://doi.org/10.1200/JCO.2015.66.3955
- Change in Palliative Performance Scale (PPS) Predicts Survival in Patients with Terminal Cancer vol.20, pp.4, 2017, https://doi.org/10.14475/kjhpc.2017.20.4.235
- Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-017-0260-1
- Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy vol.8, pp.1664-3224, 2017, https://doi.org/10.3389/fimmu.2017.00774